Pfizer (PFE) Total Liabilities (2009 - 2026)
Pfizer (PFE) posted quarterly Total Liabilities of $117.2 billion for Q1 2026, little changed year-over-year from $117.4 billion in Q1 2025, and down 3.44% quarter-over-quarter from $121.4 billion in Q4 2025.
Pfizer (PFE) Total Liabilities (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Total Liabilities for 18 consecutive years, with $117.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities changed 0.15% year-over-year to $117.2 billion; the TTM figure through Mar 2026 stood at $117.2 billion (changed 0.15% YoY), while the FY2025 annual figure was $121.4 billion, down 2.81% from the prior year.
- Total Liabilities fell to $117.2 billion in Q1 2026 per PFE's latest filing, from $121.4 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $137.2 billion in Q4 2023 and bottomed at $21.9 billion in Q3 2023.
- Historically, Total Liabilities has averaged $106.1 billion across 5 years, with a median of $117.2 billion in 2026.
- On a YoY basis, Total Liabilities climbed as much as 480.54% in 2024 and fell as far as 8.97% in 2024.
- Pfizer's Total Liabilities stood at $101.3 billion in 2022, then soared by 35.47% to $137.2 billion in 2023, then dropped by 8.97% to $124.9 billion in 2024, then fell by 2.81% to $121.4 billion in 2025, then dropped by 3.44% to $117.2 billion in 2026.
- Business Quant data shows PFE's Total Liabilities at $117.2 billion in Q1 2026, $121.4 billion in Q4 2025, and $115.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 115.64 Bn |
| Mar 29, 2026 | 117.21 Bn |
| Dec 31, 2025 | 121.39 Bn |
| Sep 28, 2025 | 115.64 Bn |
| Jun 29, 2025 | 117.08 Bn |
| Mar 30, 2025 | 117.39 Bn |
| Dec 31, 2024 | 124.90 Bn |
| Sep 29, 2024 | 126.92 Bn |
| Jun 30, 2024 | 128.22 Bn |
| Mar 31, 2024 | 128.54 Bn |
| Dec 31, 2023 | 137.21 Bn |
| Sep 30, 2023 | 21.86 Bn |
| Jul 2, 2023 | 120.88 Bn |
| Apr 2, 2023 | 94.38 Bn |
| Dec 31, 2022 | 101.29 Bn |
| Sep 30, 2022 | 22.46 Bn |
| Jul 3, 2022 | 107.82 Bn |
| Apr 3, 2022 | 101.16 Bn |
| Dec 31, 2021 | 104.01 Bn |
| Oct 3, 2021 | 10.35 Bn |